COST-EFFECTIVENESS OF EMPAGLIFLOZIN (JARDIANCE) IN THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK BASED ON EMPA-REG OUTCOME DATA

被引：10
|
作者：
Daacke, I [1 ]
Kandaswamy, P. [2 ]
Tebboth, A. [3 ]
Kansal, A. [4 ]
Reifsnider, O. [4 ]
机构：
[1] Boehringer Ingelheim GmbH & Co KG, Bracknell, Berks, England
[2] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[3] Boehringer Ingelheim UK, Bracknell, Berks, England
[4] Evidera, Bethesda, MD USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.1876
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB46
引用
收藏
页码：A673 / A673
页数：1
相关论文
共 50 条
  • [21] THE COST-EFFECTIVENESS OF SAXAGLIPTIN VERSUS NPH INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN POLAND
    Kolasa, K.
    Niewada, M.
    de Troconiz, J. Puelles Fernandez
    Townsend, R.
    McEwan, P.
    VALUE IN HEALTH, 2010, 13 (07) : A290 - A290
  • [22] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy: A Subanalysis of the EMPA-REG OUTCOME Trial
    Verma, Subodh
    Mazer, C. David
    Bhatt, Deepak L.
    Raj, Satish R.
    Yan, Andrew T.
    Verma, Atul
    Ferrannini, Ele
    Simons, Gudrun
    Lee, Jisoo
    Zinman, Bernard
    George, Jyothis T.
    Fitchett, David
    DIABETES CARE, 2019, 42 (03) : E42 - E44
  • [23] Effects of Empagliflozin on Cardiac and Vascular Hemodynamic Markers by Subgroups of Age, Sex, and Hypertension in Patients with T2DM and High CV Risk: EMPA-REG OUTCOME
    Chilton, Robert J.
    Gullestad, Lars
    Fitchett, David
    Inzucchi, Silvio E.
    Mattheus, Michaela
    Woerle, Hans Juergen
    Johansen, Odd Erik
    DIABETES, 2017, 66 : A119 - A119
  • [24] Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial
    Wanner, Christoph
    Heerspink, Hiddo J. L.
    Zinman, Bernard
    Inzucchi, Silvio E.
    Koitka-Weber, Audrey
    Mattheus, Michaela
    Hantel, Stefan
    Woerle, Hans-Juergen
    Broedl, Uli C.
    von Eynatten, Maximilian
    Groop, Per-Henrik
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (11): : 2755 - 2769
  • [25] COST-EFFECTIVENESS OF EMPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN ARGENTINA
    Rodriguez, L.
    Lew, D.
    VALUE IN HEALTH, 2020, 23 : S115 - S115
  • [26] Empagliflozin (EMPA) for ≥76 Weeks As Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans-Juergen
    Broedl, Uli C.
    ENDOCRINE REVIEWS, 2014, 35 (03)
  • [27] Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOMEA®
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Hehnke, Uwe
    George, Jyothis T.
    Johansen, Odd Erik
    Fitchett, David
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    Strivay, M.
    Vereecken, G.
    Keymeulen, B.
    DIABETOLOGIA, 2018, 61 (07) : 1522 - 1527
  • [28] Empagliflozin (EMPA) for ≥76 Weeks as Add-on to Metformin in Patients with Type 2 Diabetes (T2DM)
    Merker, Ludwig
    Haering, Hans-Ulrich
    Christiansen, Anita Vedel
    Roux, Flavien
    Salsali, Afshin
    Kim, Gabriel
    Meinicke, Thomas
    Woerle, Hans J.
    Broedl, Uli C.
    DIABETES, 2014, 63 : A278 - A278
  • [29] Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome
    Chilton, R. J.
    Gullestad, L.
    Fitchett, D.
    Inzucchi, S. E.
    Mattheus, M.
    Woerle, H. J.
    Johansen, O. E.
    EUROPEAN HEART JOURNAL, 2017, 38 : 1251 - 1251
  • [30] Association Of Kidney And Cardiovascular Outcomes: Insights From The Empagliflozin Cardiovascular Outcome Event Trial In Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) Trial
    Sharma, Abhinav
    Inzucchi, Silvio E.
    Testani, Jeffrey
    Ofstad, Anne-Pernille
    Fitchett, David
    Mattheus, Michaela
    Verma, Subodh
    Zannad, Faiez
    Wanner, Christoph
    Kraus, Bettina J.
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (05) : S103 - S103
12345